Form 4: Aligos Therapeutics Director Trades Stock Options

Aligos Therapeutics Director Heather Preston acquired stock options for 5,860 shares of common stock.

Summary

• Heather Preston, a Director at Aligos Therapeutics, Inc., acquired stock options on June 25, 2026.
• The options grant the right to buy 5,860 shares of common stock at an exercise price of $5.50 per share.
• These options are set to expire on June 25, 2036.
• The shares subject to the option will vest 100% on the first anniversary of the grant date or immediately before the 2027 annual meeting, provided continuous service is maintained.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard compensation practice for a director rather than a significant strategic move or financial performance indicator.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The vesting schedule indicates a forward-looking commitment from the director, tied to the company's performance and continuous service through at least the first anniversary of the grant date or the 2027 annual meeting.

Industry Context

StockSavvy.ai notes that insider option grants are common in the biotechnology sector as a means of incentivizing key personnel and aligning their interests with shareholders, particularly during periods of development and potential growth.

Stakeholder Impact

• Shareholders: The grant of options to a director is a standard compensation practice and may be viewed positively as it aligns director interests with long-term company value. However, it also represents potential future dilution if exercised.
• Employees: May view this as a sign of continued investment in leadership, potentially boosting morale.
• Management: Reinforces the compensation structure for executive and director roles.

Next Steps

• Director Heather Preston will continue to serve Aligos Therapeutics.
• The stock options will vest according to the schedule outlined in the filing.

Key Dates

Keywords

stock options, insider trading, Aligos Therapeutics, ALGS, director compensation, equity award